Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.82
MDCO's Cash to Debt is ranked lower than
64% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. MDCO: 0.82 )
Ranked among companies with meaningful Cash to Debt only.
MDCO' s 10-Year Cash to Debt Range
Min: 0.82  Med: 10000.00 Max: No Debt
Current: 0.82
Equity to Asset 0.47
MDCO's Equity to Asset is ranked lower than
72% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. MDCO: 0.47 )
Ranked among companies with meaningful Equity to Asset only.
MDCO' s 10-Year Equity to Asset Range
Min: 0.44  Med: 0.77 Max: 0.89
Current: 0.47
0.44
0.89
F-Score: 2
Z-Score: 1.60
M-Score: -3.60
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -23.80
MDCO's Operating margin (%) is ranked lower than
84% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.92 vs. MDCO: -23.80 )
Ranked among companies with meaningful Operating margin (%) only.
MDCO' s 10-Year Operating margin (%) Range
Min: -401.44  Med: -4.69 Max: 14.87
Current: -23.8
-401.44
14.87
Net-margin (%) -10.96
MDCO's Net-margin (%) is ranked lower than
81% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.96 vs. MDCO: -10.96 )
Ranked among companies with meaningful Net-margin (%) only.
MDCO' s 10-Year Net-margin (%) Range
Min: -385.2  Med: -3.45 Max: 29.79
Current: -10.96
-385.2
29.79
ROE (%) -6.74
MDCO's ROE (%) is ranked lower than
76% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.43 vs. MDCO: -6.74 )
Ranked among companies with meaningful ROE (%) only.
MDCO' s 10-Year ROE (%) Range
Min: -339.01  Med: -3.55 Max: 35
Current: -6.74
-339.01
35
ROA (%) -3.21
MDCO's ROA (%) is ranked lower than
74% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. MDCO: -3.21 )
Ranked among companies with meaningful ROA (%) only.
MDCO' s 10-Year ROA (%) Range
Min: -183.56  Med: -4.54 Max: 24.65
Current: -3.21
-183.56
24.65
ROC (Joel Greenblatt) (%) -87.08
MDCO's ROC (Joel Greenblatt) (%) is ranked lower than
83% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.24 vs. MDCO: -87.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDCO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -16443.26  Med: -60.11 Max: 300.56
Current: -87.08
-16443.26
300.56
Revenue Growth (3Y)(%) 8.10
MDCO's Revenue Growth (3Y)(%) is ranked higher than
54% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. MDCO: 8.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDCO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 10.00 Max: 88.9
Current: 8.1
0
88.9
EBITDA Growth (3Y)(%) -47.60
MDCO's EBITDA Growth (3Y)(%) is ranked lower than
95% of the 494 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. MDCO: -47.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MDCO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -33.90 Max: -8.2
Current: -47.6
» MDCO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

MDCO Guru Trades in Q3 2014

Vanguard Health Care Fund 4,762,730 sh (+1.33%)
Chuck Royce 6,729,175 sh (+1.10%)
George Soros Sold Out
RS Investment Management 477,466 sh (-1.52%)
Joel Greenblatt 24,009 sh (-87.68%)
» More
Q4 2014

MDCO Guru Trades in Q4 2014

Steven Cohen 221,600 sh (New)
Vanguard Health Care Fund 5,461,430 sh (+14.67%)
Joel Greenblatt Sold Out
RS Investment Management 476,998 sh (-0.10%)
Chuck Royce 4,647,740 sh (-30.93%)
Chuck Royce 4,647,740 sh (-30.93%)
» More
Q1 2015

MDCO Guru Trades in Q1 2015

Paul Tudor Jones 9,000 sh (New)
Steven Cohen 273,500 sh (+23.42%)
Vanguard Health Care Fund 5,564,220 sh (+1.88%)
RS Investment Management 338,358 sh (-29.07%)
Chuck Royce 2,081,370 sh (-55.22%)
» More
Q2 2015

MDCO Guru Trades in Q2 2015

RS Investment Management 367,318 sh (+8.56%)
RS Investment Management 367,318 sh (+8.56%)
Vanguard Health Care Fund 5,564,220 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Chuck Royce 202,932 sh (-90.25%)
Chuck Royce 202,932 sh (-90.25%)
» More
» Details

Insider Trades

Latest Guru Trades with MDCO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 86.96
MDCO's Forward P/E is ranked lower than
92% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.47 vs. MDCO: 86.96 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.77
MDCO's P/B is ranked higher than
62% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. MDCO: 2.77 )
Ranked among companies with meaningful P/B only.
MDCO' s 10-Year P/B Range
Min: 1.14  Med: 2.51 Max: 8.48
Current: 2.77
1.14
8.48
P/S 4.56
MDCO's P/S is ranked lower than
57% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. MDCO: 4.56 )
Ranked among companies with meaningful P/S only.
MDCO' s 10-Year P/S Range
Min: 0.9  Med: 2.77 Max: 10.46
Current: 4.56
0.9
10.46
Shiller P/E 79.50
MDCO's Shiller P/E is ranked lower than
78% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.72 vs. MDCO: 79.50 )
Ranked among companies with meaningful Shiller P/E only.
MDCO' s 10-Year Shiller P/E Range
Min: 25.91  Med: 53.33 Max: 748.5
Current: 79.5
25.91
748.5
Current Ratio 3.16
MDCO's Current Ratio is ranked higher than
64% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. MDCO: 3.16 )
Ranked among companies with meaningful Current Ratio only.
MDCO' s 10-Year Current Ratio Range
Min: 0.75  Med: 4.24 Max: 10.09
Current: 3.16
0.75
10.09
Quick Ratio 2.55
MDCO's Quick Ratio is ranked higher than
66% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. MDCO: 2.55 )
Ranked among companies with meaningful Quick Ratio only.
MDCO' s 10-Year Quick Ratio Range
Min: 0.75  Med: 3.63 Max: 9.44
Current: 2.55
0.75
9.44
Days Inventory 176.69
MDCO's Days Inventory is ranked lower than
77% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 111.99 vs. MDCO: 176.69 )
Ranked among companies with meaningful Days Inventory only.
MDCO' s 10-Year Days Inventory Range
Min: 15.56  Med: 131.57 Max: 1606.52
Current: 176.69
15.56
1606.52
Days Sales Outstanding 33.09
MDCO's Days Sales Outstanding is ranked higher than
83% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.80 vs. MDCO: 33.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDCO' s 10-Year Days Sales Outstanding Range
Min: 26.9  Med: 50.22 Max: 156.75
Current: 33.09
26.9
156.75

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.91
MDCO's Price/Projected FCF is ranked higher than
54% of the 319 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.70 vs. MDCO: 2.91 )
Ranked among companies with meaningful Price/Projected FCF only.
MDCO' s 10-Year Price/Projected FCF Range
Min: 0.84  Med: 1.51 Max: 11.15
Current: 2.91
0.84
11.15
Price/Median PS Value 1.67
MDCO's Price/Median PS Value is ranked lower than
57% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. MDCO: 1.67 )
Ranked among companies with meaningful Price/Median PS Value only.
MDCO' s 10-Year Price/Median PS Value Range
Min: 0.35  Med: 1.35 Max: 65.44
Current: 1.67
0.35
65.44
Earnings Yield (Greenblatt) (%) -2.09
MDCO's Earnings Yield (Greenblatt) (%) is ranked lower than
77% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. MDCO: -2.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDCO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -2.08  Med: 3.20 Max: 15.2
Current: -2.09
-2.08
15.2
Forward Rate of Return (Yacktman) (%) -16.99
MDCO's Forward Rate of Return (Yacktman) (%) is ranked lower than
88% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.88 vs. MDCO: -16.99 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MDCO' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -16.9  Med: 1.90 Max: 5.2
Current: -16.99
-16.9
5.2

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 359 270 394 637
EPS($) -1.85 -0.41 -0.26 1.29
EPS without NRI($) -1.85 -0.41 -0.26 1.29

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:MZN.Germany,
The Medicines Company was incorporated in Delaware on July 31, 1996. The Company is a global biopharmaceutical company focused on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on 3,000 acute and intensive care hospitals worldwide. The Company markets products including; Angiomax (bivalirudin), Recothrom Thrombin, topical (Recombinant), Cleviprex (clevidipine) injectable emulsion and Minocin IV (Minocycline for Injection). Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound. Recothrom is a surgical hemostat that is applied topically during surgery to stop bleeding. Cleviprex is an intravenous small molecule calcium channel blocker. Minocin IV is an Tetracycline-class antibiotic used for treatment of bacterial infections caused by Acinetobacter species. The Company has a pipeline of acute and intensive care hospital products in development, including five registration stage product candidates; cangrelor, oritavancin, IONSYSTM (fentanyl iontophoretic transdermal system), Fibrocaps and RPX-602, and three research and development product candidates, MDCO-216, CarbavanceTM and ALN-PCSsc. In addition to these products and product candidates company also sells a ready-to-use formulation of Argatroban and have a portfolio of ten generic drugs, referred to as acute care generic products, that have the non-exclusive right to market in the United States. The Company is currently selling three of its acute care generic products, midazolam, ondansetron and rocuronium; and also co-promote the oral tablet antiplatelet medicine BRILINTA (ticagrelor) in the United States as part of global collaboration agreement with AstraZeneca LP and the Boston Scientific Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, or the Promus PREMIER Stent System, in the United States under its co-promotion agreement with Boston Scientific Corporation, or BSX. It faces competition from pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. The Company and its customers are subject to extensive regulation by the federal government, and the governments of the states and foreign countries in which it may conduct its business. In addition to regulations in the United States, the Company is subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of its products.
» More Articles for MDCO

Headlines

Articles On GuruFocus.com
Netflix Profit Above Consensus, Panera Bread Boosts Buyback Plan, Medicines Co Cangrelor Well-Recomm Apr 16 2015 
Chuck Royce Buys Stifel Financial, Tidewater, Alamos, Sells Kennametal, Gardner Denver, Gartner Apr 25 2013 
Weekly CFO Sells Highlight: BK, MDCO, EBAY, MS, PHMD Jan 27 2013 
Weekly CFO Sells Highlight: MDCO, SIG, VCI, PHMD, SNPS Jan 21 2013 
George Soros' Top Buys in the Last Quarter Dec 23 2011 
George Soros Buys Amazon.com Inc., Motorola Solutions, Sandisk, Sells Ralph Lauren, Dendreon, Lawson Nov 15 2011 
Medicines Company (MDCO) Chairman & CEO Clive Meanwell sells 100,000 Shares Mar 01 2011 
Medicines Company Reports Operating Results (10-Q) Nov 09 2010 
Medicines Company Reports Operating Results (10-Q) May 10 2010 
Medicines Company (MDCO) Chairman & CEO Clive Meanwell sells 181,500 Shares May 04 2010 

More From Other Websites
Regeneron and Sanofi Present Encouraging Praluent Data Sep 02 2015
Trevena's Postoperative Pain Drug Positive in Phase IIb Study Sep 01 2015
MATRIX Trial Results Presented at Hot Line Session of ESC Congress 2015 and Simultaneously Published... Sep 01 2015
12:31 pm The Medicines Co confirms NEJM has published results from the antithrombin program of the... Sep 01 2015
MATRIX Trial Results Presented at Hot Line Session of ESC Congress 2015 and Simultaneously Published... Sep 01 2015
MATRIX Trial Results Presented at Hot Line Session of ESC Congress 2015 and Simultaneously Published... Sep 01 2015
Will Alnylam's New PCSK-9 Cholesterol Lowering Drug Be A Blockbuster? Sep 01 2015
Company News for September 01, 2015 Sep 01 2015
Analysis from CHAMPION PHOENIX Trial Highlight the Efficacy of Cangrelor among Patients undergoing... Sep 01 2015
Analysis from CHAMPION PHOENIX Trial Highlight the Efficacy of Cangrelor among Patients undergoing... Sep 01 2015
Analysis from CHAMPION PHOENIX Trial Highlight the Efficacy of Cangrelor among Patients undergoing... Sep 01 2015
Medicines Co., Alnylam Jump Ahead In Cholesterol Race Aug 31 2015
Alnylam Presents Positive Data on PCSK9 Synthesis Inhibitor Aug 31 2015
Mid-Afternoon Market Update: NASDAQ Down 1.3%; Medicines Company Shares Gain Following Announcement... Aug 31 2015
3 High-Volume Stocks to Trade Now (or Not) Aug 31 2015
Mid-Day Market Update: Crude Oil Surges 5.5%; ConforMIS Shares Tumble Aug 31 2015
Medicines (MDCO) Stock Skyrockets Following Promising Cholesterol Drug Results Aug 31 2015
The Medicines Company (MDCO) and Alnylam Pharmaceuticals Inc. (ALNY)’s Positive Phase I Results... Aug 31 2015
Mid-Morning Market Update: Markets Open Lower; Carlyle Group To Acquire Blyth For $6/Share Aug 31 2015
Medicines Shares Surge on Cholesterol-Drug Data Aug 31 2015
The Medicines Company and Alnylam Rise on Positive Phase 1 Results Aug 31 2015
The Medicines Company Appoints Dr. Fred Eshelman as Non-Executive Chairman of the Board Aug 31 2015
Medicines shares surge on upbeat cholesterol drug study Aug 31 2015
Medicines shares surge on upbeat cholesterol drug study Aug 31 2015
MEDICINES CO /DE Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale... Aug 31 2015
The Medicines Company Appoints Dr. Fred Eshelman as Non-Executive Chairman of the Board Aug 31 2015
Cholesterol-fighting 'game changer': Alnylam CEO Aug 31 2015
ALN-PCSsc Achieves Quarterly and Potentially Bi-Annual Subcutaneous Dose Regimen Profile for... Aug 30 2015
Alnylam, Medicines cholesterol drug lasts months after one shot Aug 30 2015
Alnylam, Medicines cholesterol drug lasts months after one shot Aug 30 2015
ALN-PCSsc Achieves Quarterly and Potentially Bi-Annual Subcutaneous Dose Regimen Profile for... Aug 30 2015
ALN-PCSsc Achieves Quarterly and Potentially Bi-Annual Subcutaneous Dose Regimen Profile for... Aug 30 2015
The Medicines Company Announces Participation at 2015 European Society of Cardiology (ESC) Congress... Aug 24 2015
The Medicines Company Announces Participation at 2015 European Society of Cardiology (ESC) Congress... Aug 24 2015
The Medicines Company (Nasdaq: MDCO) to Ring The Nasdaq Stock Market Opening Bell Aug 07 2015
Medicines Co. reports 2Q loss Jul 29 2015
The Medicines Company Reports Second-Quarter and First-Half 2015 Financial Results Jul 29 2015
The Medicines Company to Announce Second Quarter Financial Results on Wednesday July 29, 2015 Jul 13 2015
The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin) Jul 09 2015
Federal Circuit Rules Against The Medicines Company in Angiomax® (bivalirudin) Patent Litigation Jul 02 2015
The Medicines Company Announces Results of Phase 1 Study for Novel Investigational Intravenous... Jun 01 2015
The Medicines Company to Hold Conference Call on Tuesday, June 2 to Discuss Clinical Trial Results... Jun 01 2015
The Medicines Company Presents New Data Showing Remodeling Effect of MDCO-216 on HDL Particles in... May 26 2015
The Medicines Company to participate in the Jefferies 2015 Healthcare Conference May 22 2015
The Medicines Company to Participate in Bank of America Merrill Lynch 2015 Health Care Conference May 07 2015
The Medicines Company Reports First Quarter 2015 Financial Results and Operational Developments May 05 2015
Medicines Co. misses 1Q revenue forecasts May 05 2015
BUZZ-U.S. STOCKS ON THE MOVE-LinkedIn, Tesla, Lloyds, CVS Health May 01 2015
The Medicines Company Announces FDA Approval of IONSYS® (fentanyl iontophoretic transdermal system)... Apr 30 2015
The Medicines Company Announces FDA Approval of RAPLIXA™ (Fibrin Sealant), the First and Only... Apr 30 2015
The Medicines Company to Announce First Quarter Financial Results on Tuesday, May 5, 2015 Apr 21 2015
Medicines Co. slumps as company forecasts big sales decline Apr 09 2015
US STOCKS-Wall St ends up on energy rebound; early earnings weak Apr 09 2015
Medicines Co. reports 4Q loss Feb 18 2015
Medicines Co. beats 3Q earnings expectations Oct 22 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK